← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E3 Erectile dysfunction and sexual desire in men | E3 | |||||||
| E4 Skin tanning (the main gray-market claim) | E4 | |||||||
| E6 Appetite suppression / weight loss (gray-market claim) | E6 |
Melanotan II
Lactam-bridged cyclic heptapeptide analogue of alpha-MSH(4-10): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, as described by Dorr et al. 1996. Contains norleucine and a D-amino acid. It differs from bremelanotide only at the C-terminus (amide rather than free acid).
Non-standard residues or modifications: no plain one-letter sequence
Also: Melanotan-II, Melanotan 2 · Codes: MT-II
A synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone that activates several melanocortin receptors. It was studied in small academic trials in the 1990s for tanning and erectile function, then not developed as a medicine. It is not approved anywhere checked and is sold online as an unlicensed injectable "tanning" product. Its documented human record is dominated by case reports of harm: changing and new moles, melanoma, priapism, rhabdomyolysis and kidney injury.
- US C gray market
- EU C gray market
- UK C gray market
- CA C gray market
- AU C gray market
- JP ? not verified
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Not approved | No FDA-approved application: openFDA Drugs@FDA returns no application with a melanotan active ingredient (query: products.active_ingredients.name:MELANOTAN*). Melanotan II does not appear in any category of FDA's 503A bulk drug substances nomination list (version updated 14 May 2026).“No matches found!”openFDA Drugs@FDA API (FDA) · retrieved 2026-10-10 |
| EU | Not approved | No entry for melanotan II in EMA's downloadable table of centrally authorised medicines (retrieved 2026-10-10). National authorisations were not checked individually; none is known.“This includes information on marketing authorisations of centrally authorised medicines and post-authorisation procedures.”EMA: Download medicine data · retrieved 2026-10-10 |
| UK | Not approved | A search of the MHRA products database index for 'melanotan' returned no authorised product documents. Historic MHRA public warnings about tanning injections were found only via secondary reports and are not cited here.“Scientific reports about marketing authorisations for medicines”MHRA Products · retrieved 2026-10-10 |
| CA | Not approved | The Health Canada Drug Product Database API returns no product with an active ingredient matching melanotan (https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=melanotan returned an empty list).“The DPD contains product specific information on drugs approved for use in Canada.”Health Canada Drug Product Database (DPD) API Guide · retrieved 2026-10-10 |
| AU | Not approved | Listed by name in Schedule 4 (Prescription Only Medicine) of the Poisons Standard (October 2026 instrument, F2026L01327, in force). No registered product was found; Schedule 4 listing controls supply and does not indicate approval.“MELANOTAN II cross reference: α–MELANOCYTE STIMULATING HORMONE Schedule 4”Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (Federal Register of Legislation) · retrieved 2026-10-10 |
| JP CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Prohibited · class S0. “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use” WADA source
02What the human evidence shows
Erectile dysfunction and sexual desire in men
Small double-blind, placebo-controlled crossover studies from a single US research group in the late 1990s reported erections after injection more often than after placebo, in men with psychogenic and with organic erectile dysfunction, and higher self-rated sexual desire. In the organic study, 12 of 19 injections initiated erections versus 1 of 21 placebo doses, and 4 of 19 injections caused severe nausea. No larger trial has been published.
- [1] More erections and higher sexual desire than placebo in a small crossover study; severe nausea after 4 of 19 injections
Registered-study counts: ClinicalTrials.gov intervention search “melanotan”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Skin tanning (the main gray-market claim)
No randomised controlled trial in humans has been published for this use.
The only published efficacy data are a pilot phase 1 study in three healthy men (single-blind, alternating days of injection and saline) in which two subjects showed increased facial and body pigmentation. No randomised trial of tanning has been published. No study has tested whether induced tanning reduces sunburn or skin cancer, and case reports describe new and changing moles in users.
- [2] Increased skin pigmentation in two of three healthy men; nausea, yawning-stretching and spontaneous erections reported
Registered-study counts: ClinicalTrials.gov intervention search “melanotan”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Appetite suppression / weight loss (gray-market claim)
No human trial of any design has been published for this use.
Reduced food intake has been shown only in rodents, for example after injection into the brain ventricles of mice. No human study has measured appetite, food intake or body weight as an outcome.
- [3] Intracerebroventricular MTII inhibited feeding in four mouse models of hyperphagia
Registered-study counts: ClinicalTrials.gov intervention search “melanotan”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT07437560 | Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo | 2 | Recruiting |
03Safety signals
There are no adequate human safety data. The absence of reported harm is not evidence of safety.
- Eruptive and changing melanocytic naevi (moles) [4]
Case reports of new and changing naevi after unlicensed injection; a review highlights melanocytic changes in existing moles and newly emerging (dysplastic) naevi. - Melanoma [5]
Case reports of melanoma and melanoma in situ arising during or shortly after use; a review counted four reported melanomas. Causation is not established, and users often also use sunbeds. - Melanoma in situ [6]
Australian case report of melanotan-associated melanoma in situ. - Ischaemic priapism [7]
Case report of acute ischaemic priapism requiring surgical decompression after injection; the authors note earlier reports. - Systemic sympathomimetic toxicity and rhabdomyolysis with kidney injury [8]
Case report after injection of an internet-purchased product. - Renal infarction [9]
Case report and literature review attributing renal infarction most likely to melanotan II. - Overall risk profile of unregulated use [10]
Review of unregulated alpha-MSH analogue use summarising cutaneous complications and uncertainties about preparation and contents.
04What is unknown
- No randomised trial of tanning efficacy, and no study of whether induced pigmentation changes sunburn or skin-cancer risk
- Incidence of naevus changes, melanoma, priapism or kidney injury among users is unknown; only case reports exist
- No human pharmacokinetic data for the injectable or nasal products sold online
- No published analytical data on identity, purity, sterility or content of gray-market products
- No long-term human safety data of any kind
- Results of the only registered current trial (NCT07437560, vitiligo, small company sponsor, recruiting) are not available
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000). doi:10.1016/s0090-4295(00)00680-4
- Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996). doi:10.1016/0024-3205(96)00160-9
- Role of melanocortinergic neurons in feeding and the agouti obesity syndrome (1997). doi:10.1038/385165a0
- Eruptive melanocytic naevi following melanotan injection. doi:10.1111/j.1365-2133.2009.09362.x
- Melanoma Associated with the Use of Melanotan-II. doi:10.1159/000356389
- Melanotan-associated melanoma in situ. doi:10.1111/j.1440-0960.2012.00915.x
- Melanotan Tanning Injection: A Rare Cause of Priapism. doi:10.1016/j.esxm.2020.100298
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. doi:10.3109/15563650.2012.740637
- Melanotan II: a possible cause of renal infarction: review of the literature and case report. doi:10.1007/s13730-020-00447-z
- Risks of unregulated use of alpha‐melanocyte‐stimulating hormone analogues: a review. doi:10.1111/ijd.13585
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
Melanotan II is a non-selective agonist at several melanocortin receptors; MC1 receptor activation on melanocytes increases melanin production, and central melanocortin receptor activation was associated with erections and reduced feeding in early human and rodent studies.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.